Cyclo Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.56
- Today's High:
- $1.7599
- Open Price:
- $1.56
- 52W Low:
- $0.67
- 52W High:
- $2.7499
- Prev. Close:
- $1.61
- Volume:
- 58648
Company Statistics
- Market Cap.:
- $22.90 million
- Book Value:
- -0.044
- Revenue TTM:
- $1.33 million
- Operating Margin TTM:
- -1327.16%
- Gross Profit TTM:
- $1.23 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -110.47%
- Return on Equity TTM:
- -280.53%
Company Profile
Cyclo Therapeutics Inc had its IPO on 2011-02-23 under the ticker symbol CYTH.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Cyclo Therapeutics Inc has a staff strength of 9 employees.
Stock update
Shares of Cyclo Therapeutics Inc opened at $1.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.56 - $1.76, and closed at $1.75.
This is a +8.7% increase from the previous day's closing price.
A total volume of 58,648 shares were traded at the close of the day’s session.
In the last one week, shares of Cyclo Therapeutics Inc have increased by +7.36%.
Cyclo Therapeutics Inc's Key Ratios
Cyclo Therapeutics Inc has a market cap of $22.90 million, indicating a price to book ratio of 2.8412 and a price to sales ratio of 8.6536.
In the last 12-months Cyclo Therapeutics Inc’s revenue was $1.33 million with a gross profit of $1.23 million and an EBITDA of $-17675002. The EBITDA ratio measures Cyclo Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cyclo Therapeutics Inc’s operating margin was -1327.16% while its return on assets stood at -110.47% with a return of equity of -280.53%.
In Q1, Cyclo Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 21.8%.
Cyclo Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cyclo Therapeutics Inc’s profitability.
Cyclo Therapeutics Inc stock is trading at a EV to sales ratio of 6.5728 and a EV to EBITDA ratio of -0.8707. Its price to sales ratio in the trailing 12-months stood at 8.6536.
Cyclo Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $4.10 million
- Total Liabilities
- $4.50 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cyclo Therapeutics Inc ended 2024 with $4.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.10 million while shareholder equity stood at $-438876.00.
Cyclo Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.50 million in other current liabilities, 1056.00 in common stock, $-68806464.00 in retained earnings and $0 in goodwill. Its cash balance stood at $915176.00 and cash and short-term investments were $915176.00. The company’s total short-term debt was $16,969 while long-term debt stood at $0.
Cyclo Therapeutics Inc’s total current assets stands at $3.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $131224.00 compared to accounts payable of $0 and inventory worth $244497.00.
In 2024, Cyclo Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cyclo Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.75
- 52-Week High
- $2.7499
- 52-Week Low
- $0.67
- Analyst Target Price
- $5
Cyclo Therapeutics Inc stock is currently trading at $1.75 per share. It touched a 52-week high of $2.7499 and a 52-week low of $2.7499. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $1.52 and 200-day moving average was $1.43 The short ratio stood at 0.21 indicating a short percent outstanding of 0%.
Around 1122.9% of the company’s stock are held by insiders while 1259.3% are held by institutions.
Frequently Asked Questions About Cyclo Therapeutics Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer’s disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.